Chalcogen Bonded Directly To The Triazole Ring Patents (Class 514/384)
-
Patent number: 8658680Abstract: Chemically stable aqueous dispersions of prothioconazole and processes for preparing them are provided. The dispersions comprise prothioconazole present in an aqueous medium, and a sulfur-containing compound present in an amount effective to render the dispersion chemically stable.Type: GrantFiled: August 9, 2011Date of Patent: February 25, 2014Assignee: Bayer Cropscience LPInventors: Fred C. Rosa, Tai-Teh Wu
-
Patent number: 8658564Abstract: The present invention relates to novel active compound combinations comprising the known fungicidally active compounds N-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, metalaxyl and triazole (3), which are highly suitable for controlling unwanted phytopathogenic fungi. Moreover, the invention relates to a method for the curative or preventive treatment of phytopathogenic fungi on plants or useful plants, in particular to the treatment of seed, for example seed of cereals, and not least to the treated seed itself.Type: GrantFiled: May 28, 2008Date of Patent: February 25, 2014Assignee: Bayer Cropscience AGInventors: Anne Suty-Heinze, Peter Dahmen
-
Publication number: 20140051665Abstract: Method for treating a subject with prostate cancer, comprising administering to the an effective amount of a compound represented by the following structural formula: a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.Type: ApplicationFiled: February 23, 2012Publication date: February 20, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: David Proia, Suqin He
-
Publication number: 20140051664Abstract: Methods for treating cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the following structural formula a tautomer, or a pharmaceutically acceptable salt thereof in combination with radiotherapy. The variables depicted in the structural formula are defined herein.Type: ApplicationFiled: February 22, 2012Publication date: February 20, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Kevin P. Foley, David Proia
-
Publication number: 20140045908Abstract: Methods for treating a subject with cancer mediated through dysregulated, aberrant, or defective JAK/STAT signaling, are provided, comprising determining the level of the JAK/STAT signaling in a sample derived from a subject in need of treatment, wherein the presence of dysregulated, aberrant, or defective JAK/STAT signaling is indicated, administering to the subject an effective amount of a triazolone compound as described herein.Type: ApplicationFiled: February 24, 2012Publication date: February 13, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Ronald K. Blackman, Kevin P. Foley, David Proia
-
Patent number: 8648104Abstract: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating c-Met associated cancers, in a subject in need thereof.Type: GrantFiled: May 22, 2008Date of Patent: February 11, 2014Assignee: Synta Pharmaceuticals Corp.Inventors: Zhenjian Du, Kevin Foley
-
Patent number: 8642278Abstract: The disclosed modulators of Rb:Raf-1 interactions are potent, selective disruptors of Rb:Raf-1 binding, with IC50 values ranging from 80 nM to 500 nM. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer. Moreover, the disclosed compounds effectively disrupt angiogenesis and significantly inhibited tumors in nude mice derived from human epithelial lung carcinoma tumors. Accordingly, the disclosed compounds, pharmaceutical compositions comprising the compounds, methods of inhibiting cell proliferation, methods of treating subjects with cancer, and methods of preparing the disclosed compounds are provided.Type: GrantFiled: November 22, 2006Date of Patent: February 4, 2014Assignee: University of South FloridaInventors: Said M. Sebti, Srikumar Chellappan, Nicholas James Lawrence
-
Patent number: 8637534Abstract: The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula and the active compound of groups (1) to (24) listed in the description have very good fungicidal properties.Type: GrantFiled: June 10, 2009Date of Patent: January 28, 2014Assignee: Bayer Intellectual Property GmbHInventors: Stefan Dutzmann, Klaus Stenzel, Manfred Jautelat
-
Patent number: 8633232Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: GrantFiled: May 4, 2012Date of Patent: January 21, 2014Assignee: Ardea Biosciences, Inc.Inventors: Esmir Gunic, Jean-Luc Girardet, Jean-Michel Vernier, Martina E. Tedder, David A. Paisner
-
Patent number: 8632767Abstract: The present invention constitutes new 3-[1-(3-haloalkyl)triazolyl]phenyl sulphide derivatives of the formula (I) in which A1, A2, B0, B1, B2, B3, R1, R2 and n are as defined in the description, to their use as acaricides and insecticides for controlling animal pests, and to processes for preparing them.Type: GrantFiled: August 19, 2010Date of Patent: January 21, 2014Assignee: Bayer Intellectual Property GmbHInventors: Bernd Alig, Stefan Antons, Reiner Fischer, Norbert Lui, Adeline Köhler, Arnd Voerste
-
Patent number: 8633233Abstract: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.Type: GrantFiled: August 6, 2009Date of Patent: January 21, 2014Assignee: Hydra Biosciences, Inc.Inventors: Jayhong Chong, Christopher Fanger, Magdalene M. Moran, Elisha Singer, Timothy Strassmaier, Howard Ng
-
Publication number: 20140018355Abstract: The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.Type: ApplicationFiled: June 27, 2013Publication date: January 16, 2014Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Timothy L. MACDONALD, Jerry L. NADLER, Peng CUI
-
Patent number: 8629169Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.Type: GrantFiled: November 15, 2011Date of Patent: January 14, 2014Assignee: Eli Lilly and CompanyInventors: Stephon Cornell Smith, Renhua Li, Charles Howard Mitch, Tatiana Natali Vetman
-
Publication number: 20140005145Abstract: Methods for treating breast cancer, comprising administering to the subject an effective amount of a selective estrogen receptor modulator and an effective amount of a compound represented by the following structural formula: (I) (Ia) a tautomer, or a pharmaceutically acceptable salt thereof. The variables depicted in the structural formula are defined herein.Type: ApplicationFiled: December 7, 2011Publication date: January 2, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventor: David Proia
-
Publication number: 20140005241Abstract: The present invention relates to compounds, compositions, and methods, for treating subjects suspected of needing treatment for a Nidovirales virus infection. In certain embodiments, the compounds comprise Nidovirales helicase inhibitors that do not significantly affect helicase ATPase enzymatic activity or nucleic acid binding activity of the helicase.Type: ApplicationFiled: June 17, 2013Publication date: January 2, 2014Applicant: The Curators of the University of MissouriInventors: Stefan G. Sarafianos, Adeyemi O. Adedeji, Kamlendra Singh
-
Publication number: 20140005136Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: ApplicationFiled: July 30, 2013Publication date: January 2, 2014Applicant: Ardea Biosciences, Inc.Inventors: Barry D. QUART, Jean-Luc GIRARDET, Esmir GUNIC, Li-Tain YEH
-
Publication number: 20130345271Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.Type: ApplicationFiled: July 30, 2013Publication date: December 26, 2013Applicant: Ardea Biosciences, Inc.Inventors: Irina ZAMANSKY, Gabriel GALVIN, Jean-Luc GIRARDET
-
Patent number: 8614241Abstract: An ester compound represented by formula (1): wherein R3 represents hydrogen or methyl, R4 represents hydrogen or C1-C4 alkyl, and R5 represents hydrogen or C1-C4 alkyl; has an excellent pest control effect and is therefore useful as an active ingredient of a pest control agent.Type: GrantFiled: March 18, 2011Date of Patent: December 24, 2013Assignee: Sumitomo Chemical Company, LimitedInventor: Noritada Matsuo
-
Publication number: 20130338155Abstract: The present invention relates to compounds that inhibit the activity of Hsp90 and methods of using these compounds for treating or preventing infection.Type: ApplicationFiled: June 4, 2013Publication date: December 19, 2013Applicant: SYNTA PHARMACEUTICALS CORP.Inventor: Weiwen Ying
-
Publication number: 20130330365Abstract: In one aspect, the invention relates to compounds having the formula X: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Publication number: 20130331403Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: Ardea Biosciences, Inc.Inventors: Laszlo R. TREIBER, Irina ZAMANSKY, Jean-Luc GIRARDET
-
Publication number: 20130331357Abstract: A composition comprising a proteasome inhibitor, and an Hsp90 inhibitor according to the following formulae (I) or (Ia), a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder such as cancer in a subject in need thereof, using pharmaceutical combinations described herein.Type: ApplicationFiled: January 10, 2012Publication date: December 12, 2013Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: David Proia, Julie Friedland
-
Publication number: 20130330366Abstract: In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.Type: ApplicationFiled: June 6, 2013Publication date: December 12, 2013Inventors: Adam D. Hughes, Melissa Fleury
-
Patent number: 8598078Abstract: Compounds of Formula I wherein the substituents are as defined in Claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: GrantFiled: August 21, 2008Date of Patent: December 3, 2013Assignee: Syngenta Crop Protection, LLCInventors: Olivier Loiseleur, Roger Graham Hall, André Denis Stoller, Gerald Wayne Craig, André Jeanguenat, Andrew Edmunds
-
Publication number: 20130303505Abstract: TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.Type: ApplicationFiled: August 11, 2010Publication date: November 14, 2013Inventors: Venkataiah Bollu, Brant Clayton Boren, Jackaline Dalgard Julien, Brenton T. Flatt, Nadia Haq, Sarah Hudson, Raju Mohan, Michael Morrissey, Benjamin Pratt
-
Publication number: 20130296345Abstract: Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).Type: ApplicationFiled: October 15, 2010Publication date: November 7, 2013Applicant: Ardea Biosciences, Inc.Inventor: Barry D. Quart
-
Publication number: 20130296322Abstract: In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: July 8, 2013Publication date: November 7, 2013Applicant: THERAVANCE, INC.Inventors: Eric L. Stangeland, Lori Jean Van Orden, Daisuke Roland Saito
-
Publication number: 20130296389Abstract: The novel active compound combinations comprising 2-[2-(1-chlorocyclopropyl)3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula and the active compound of groups (1) to (24) listed in the description have very good fungicidal properties.Type: ApplicationFiled: March 5, 2013Publication date: November 7, 2013Inventor: Bayer Intellectual Property GmbH
-
Publication number: 20130274256Abstract: Certain multi-cyclic compounds and compositions thereof are useful for reducing or inhibiting the growth of bacterial biofilms and for controlling bacterial biofilm infections. Such compounds and compositions are also useful in methods for reducing or inhibiting the growth of biofilms and for controlling bacterial biofilm infections involving biofilms.Type: ApplicationFiled: October 11, 2012Publication date: October 17, 2013Applicant: SEQUOIA SCIENCES, INC.Inventor: Sequoia Sciences, Inc.
-
Patent number: 8552043Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O) N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.Type: GrantFiled: December 6, 2011Date of Patent: October 8, 2013Assignee: Ardea Biosciences, Inc.Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Zhi Hong, Stanley Lang
-
Patent number: 8546437Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.Type: GrantFiled: June 30, 2011Date of Patent: October 1, 2013Assignee: Ardea Biosciences, Inc.Inventors: Barry D. Quart, Jean-Luc Girardet, Esmir Gunic, Li-Tain Yeh
-
Patent number: 8546436Abstract: Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.Type: GrantFiled: December 28, 2011Date of Patent: October 1, 2013Assignee: Ardea Biosciences, Inc.Inventors: Laszlo R. Treiber, Gabriel Galvin, Irina Zamansky, Jean-Luc Girardet
-
Publication number: 20130252818Abstract: An amorphous formulation of a herbicidal or pesticidal substance includes a composition of the formula [A]x[MpClq]y, the composition being an ionic liquid with a melting temperature below 150° C., wherein [MpClq] is a metal chloride, x is 1, 2, 3, or 4, p is 1, 2, 3, or 4, q is 1, 2, 3, 4, 5, 6, 7, 8, or 9, and y is 1 or 2, wherein each A is a cation that is a herbicidal or pesticidal substance or a cation precursor that is a herbicidal or pesticidal substance.Type: ApplicationFiled: March 25, 2013Publication date: September 26, 2013Inventors: Katherine Lovejoy, Rico Del Sesto, Andrew Koppisch
-
Publication number: 20130237573Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.Type: ApplicationFiled: November 15, 2011Publication date: September 12, 2013Applicant: ELI LILLY AND COMPANYInventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
-
Patent number: 8530381Abstract: The invention relates to active compound combinations, in particular within a composition, which comprises (A) an amidine compound of formula (I) and a further fungicidally (B-1), insecticidally (B-2) active or plant growth regulating compound (B-3). Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or reducing the mycotoxin contamination of plant or plant parts, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: GrantFiled: December 16, 2010Date of Patent: September 10, 2013Assignee: Bayer CropScience AGInventors: Kerstin Ilg, Ulrich Heinemann, Peter Dahmen, Ulrike Wachendorff-Neumann
-
Publication number: 20130231313Abstract: The present application relates to novel substituted phenylacetamides and phenylpropanamides, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: September 14, 2011Publication date: September 5, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Chantal Fürstner, Joerg Keldenich, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel
-
Patent number: 8524754Abstract: Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.Type: GrantFiled: January 5, 2011Date of Patent: September 3, 2013Assignee: Ardea Biosciences, Inc.Inventors: Irina Zamansky, Jean-Luc Girardet, Gabriel Galvin
-
Publication number: 20130225646Abstract: The present application relates to novel substituted N-phenethyltriazoloneacetamides, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: August 31, 2011Publication date: August 29, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Chantal Fürstner, Joerg Keldenich, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Elisabeth Pook, Carsten Schmeck, Hubert Trübel
-
Publication number: 20130217685Abstract: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.Type: ApplicationFiled: January 8, 2013Publication date: August 22, 2013Applicant: UNIVERSITY OF MASSACHUSETTSInventor: University of Massachusetts
-
Publication number: 20130196981Abstract: Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) in which A, R1, R2 and R3 are as defined in the description, and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.Type: ApplicationFiled: March 13, 2013Publication date: August 1, 2013Applicant: Bayer Intellectual Property GmbHInventor: Bayer Intellectual Property GmbH
-
Publication number: 20130190371Abstract: The novel active compound combinations comprising 2-[2-(1-chorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione of the formula and the active compound of groups (1) to (24) listed in the description have very good fungicidal properties.Type: ApplicationFiled: January 15, 2013Publication date: July 25, 2013Applicant: Bayer Intellectual Property GmbHInventor: Bayer Intellectual Property GmbH
-
Publication number: 20130190330Abstract: The present application relates to novel bisaryl-linked 5-aryl-1,2,4-triazolone derivatives, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.Type: ApplicationFiled: February 25, 2011Publication date: July 25, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Chantal Furstner, Joerg Keldenich, Martina Delbeck, Peter Kolkhof, Axel Kretschmer, Ingo Pluschkell, Elisabeth Pook, Carsten Schmeck, Hubert Trubel
-
Publication number: 20130184152Abstract: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) prothioconazole and (B) fluxapyroxad and optionally (C) a further fungicidally active compound. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi of plants or crops (e.g. cereals such as wheat, barley, rye, oats, millet and triticale; soya beans; rice; com/maize; oil seed rape including canola; beans, peas, peanuts; sugar beet, fodder beet, beetroot; potatoes; cotton), and to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.Type: ApplicationFiled: August 2, 2011Publication date: July 18, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventor: Stephanie Gary
-
Patent number: 8486932Abstract: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a pharmaceutical composition comprising such a compound.Type: GrantFiled: December 21, 2011Date of Patent: July 16, 2013Assignee: Synta Pharmaceuticals Corp.Inventors: Joseph A. Burlison, Shijie Zhang, Weiwen Ying, Dinesh U. Chimmanamada, Minghu Song, Junghyun Chae, Stefan Schweizer
-
Publication number: 20130178484Abstract: Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.Type: ApplicationFiled: June 14, 2011Publication date: July 11, 2013Applicant: Ardea Biosciences, Inc.Inventors: Jeffrey Miner, Jean-Luc Girardet, Barry D. Quart
-
Patent number: 8481581Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.Type: GrantFiled: July 18, 2012Date of Patent: July 9, 2013Assignee: Ardea Biosciences, Inc.Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Hong-Woo Kim
-
Patent number: 8481580Abstract: The present invention provides analogs of a Lysofylline (LSF), and synthetic methods for the preparation of such analogs. The have the active side chain moiety (5-R-hydroxyhexyl) of LSF and can have greater potency and oral bioavailability than LSF.Type: GrantFiled: February 25, 2008Date of Patent: July 9, 2013Assignee: University of Virginia Patent FoundationInventors: Timothy L. Macdonald, Jerry L. Nadler, Peng Cui
-
Publication number: 20130172333Abstract: Provided is a pharmaceutical composition comprising a pharmaceutically acceptable organic solvent, a pharmaceutically acceptable surfactant, and a compound according to the following formula: wherein the variables are defined herein. Optionally, the pharmaceutical composition further comprises a co-solvent. Also provided is a method of using the pharmaceutical composition disclosed herein for the treatment of a patient in need thereof.Type: ApplicationFiled: May 20, 2011Publication date: July 4, 2013Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Neera Jain, Suresh R. Babu, Shweta Kotecha, Hong Yang
-
Publication number: 20130171105Abstract: A pharmaceutical combination comprising a topoisomerase II inhibitor, and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided is a method for treating a proliferative disorder in a subject in need thereof, using the pharmaceutical combination described herein.Type: ApplicationFiled: May 23, 2011Publication date: July 4, 2013Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Ronald K. Blackman, Kevin Paul Foley, David Proia
-
Publication number: 20130172384Abstract: This invention relates to the use of triazolone and triazolethione derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones and triazolethiones in the treatment of cancer.Type: ApplicationFiled: September 15, 2011Publication date: July 4, 2013Inventors: Nicholas D. Adams, Christopher Joseph Aquino, Jonathan M. Ghergurovich, David Lee Musso, Cynthia A. Parrish